14 completed, 2 terminated, 2 unknown, 1 withdrawn. 4 Phase 3, 3 Not applicable, 3 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Not applicable | 3 | Completed 3 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Human Immunodeficiency Virus Infection: new trials by email Literature Review of Human Immunodeficiency Virus Infection trials Research Report on Human Immunodeficiency Virus Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HPV Infection, Sexually Transmitted Infections and Anal Dysplasia in the Transgender Population Human Papillomavirus Infection, Human Immunodeficiency Virus Infection | Completed | ANRS, Emerging Infectious Diseases | 200 | 2024-10-15 | 2026-09-02 | |
| Awareness of Osteoporosis in HIV Patients Patient Participation Form - Human Immunodeficiency Virus Infection, Osteoporosis | Unknown | Uskudar State Hospital | 400 | 2023-08-01 | 2023-05-23 | |
| A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers SHR2150 tablet、efavirenz - Human Immunodeficiency Virus Infection | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2021-12-13 | 2021-12-20 |
| Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily - Human Immunodeficiency Virus Infection | Completed | Obafemi Awolowo University | 194 | 2017-12-22 | 2020-10-14 | |
| Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men AWARENESS for Sexual Minorities, Writing tasks - Human Immunodeficiency Virus Infection, Inflammation | Not applicable | Completed | University of California, San Francisco | 40 | 2017-05-05 | 2024-10-22 |
| DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine - Diphtheria, Tetanus | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 53 | 2016-07-14 | 2022-04-05 |
| A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) ABT-493 coformulated with ABT-530 - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection | Phase 3 | Completed | AbbVie | 153 | 2016-05-17 | 2021-07-13 |
| The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV rice bran arabinoxylan compound (RBAC), Placebo - Human Immunodeficiency Virus Infection | Not applicable | Completed | University of Miami | 47 | 2015-01-01 | 2016-07-18 |
| A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection ABT-450/r/ABT-267, ABT-333, ribavirin - Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection | Phase 2 / Phase 3 | Completed | AbbVie | 318 | 2013-08-30 | 2021-07-12 |
| Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART darunavir with ritonavir and fixed-dose viread+emtricitabine daily - Human Immunodeficiency Virus Infection | Phase 4 | Completed | University of California, Davis | 37 | 2013-06-01 | 2020-03-04 |
| A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects amdoxovir 300 mg bid, amdoxovir 500 mg bid - Human Immunodeficiency Virus Infection | Phase 2 | Withdrawn | RFS Pharma, LLC | 2013-04-01 | 2013-03-29 | |
| Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults extended-release exenatide - Human Immunodeficiency Virus Infection, Diabetes Mellitus | Phase 4 | Terminated | Vanderbilt University | 6 | 2013-03-01 | 2017-03-10 |
| A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects. amdoxovir 300 mg bid, amdoxovir 500 mg bid, tenofovir DF 300 mg qd - Human Immunodeficiency Virus Infection | Phase 2 | Terminated | RFS Pharma, LLC | 2 | 2012-12-01 | 2014-11-05 |
| Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program Lopinavir / ritonavir, Kaletra Adherence Support Assistance Program - Human Immunodeficiency Virus Infection | Completed | AbbVie (prior sponsor, Abbott) | 173 | 2012-06-01 | 2018-01-29 | |
| Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing Human Immunodeficiency Virus Infection, Hepatitis C | Completed | G & W Laboratories Inc. | 1600 | 2011-08-01 | 2015-09-07 | |
| Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection Human Immunodeficiency Virus Infection | Completed | AbbVie (prior sponsor, Abbott) | 236 | 2011-06-01 | 2014-12-22 | |
| Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) Human Immunodeficiency Virus Infection | Completed | AbbVie (prior sponsor, Abbott) | 97 | 2011-06-01 | 2013-05-06 | |
| Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL) - Human Immunodeficiency Virus Infection | Phase 3 | Completed | Abbott | 206 | 2008-07-01 | 2012-02-14 |
| Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men Men Making a Difference HIV/STD Risk Reduction Intervention, Health Promotion Control - Human Immunodeficiency Virus Infection, Sexually Transmitted Diseases | Not applicable | Completed | University of Pennsylvania | 1181 | 2007-11-01 | 2017-12-19 |
Acquired Immunodeficiency Syndrome (19) · Hepatitis C (3) · HIV Infections (2) · Hepatitis C, Chronic (2) · Infections (2) · Sexually Transmitted Diseases (2) · Diabetes Mellitus (1) · Diphtheria (1) · Hepatitis B (1) · Inflammation (1) · Metabolic Syndrome (1) · Multiple Endocrine Neoplasia Type 1 (1) · Osteoporosis (1) · Papillomavirus Infections (1) · Poliomyelitis (1)
Blood-Borne Infections (19) · Communicable Diseases (19) · Genital Diseases (19) · Immune System Diseases (19) · Immunologic Deficiency Syndromes (19) · Lentivirus Infections (19) · RNA Virus Infections (19) · Retroviridae Infections (19) · Sexually Transmitted Diseases, Viral (19) · Slow Virus Diseases (19) · Urogenital Diseases (19) · Virus Diseases (19) · HIV Infections (17) · Infections (17) · Sexually Transmitted Diseases (17)
Tenofovir (3) · BID protein, human (2) · Lopinavir (2) · amdoxovir (2) · lopinavir-ritonavir drug combination (2) · DTaP-IPV-HB-PRP-T vaccine (1) · Darunavir (1) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Exenatide (1) · Lamivudine (1) · Raltegravir Potassium (1) · Ribavirin (1) · Ritonavir (1) · Zidovudine (1)
AbbVie (prior sponsor, Abbott) (3) · AbbVie (2) · RFS Pharma, LLC (2) · ANRS, Emerging Infectious Diseases (1) · Abbott (1) · G & W Laboratories Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Obafemi Awolowo University (1) · Sanofi Pasteur, a Sanofi Company (1) · University of California, Davis (1) · University of California, San Francisco (1) · University of Miami (1) · University of Pennsylvania (1) · Uskudar State Hospital (1) · Vanderbilt University (1)
United States (6) · France (2) · Spain (2) · Argentina (1) · Canada (1) · China (1) · Italy (1) · Japan (1) · Nigeria (1) · Poland (1) · Puerto Rico (1) · South Africa (1)
Luz Pascual, MD MPH (2) · Adeniyi Olagunju, PhD (1) · Angel Burgos, PhD (1) · C. William Wester, MD (1) · Christina Pelizon, MD (1) · John E Lewis, Ph.D. (1) · John Koethe, MD (1) · Mustafa H Temel, M.D. (1) · Niel Constantine, Ph.D. (1) · Rolando Viani, MD (1) · Susumu Adachi, MD (1)
PMID 22180523, PMID 22730929, PMID 24432923, PMID 24736094, PMID 25565482, PMID 25969177, PMID 26743093, PMID 27919899, PMID 28412293, PMID 30529905, PMID 30868245, PMID 30977945, PMID 38859656, PMID 38934229, PMID 39992775
2008 (1), 2015 (1), 2018 (1), K23DA039800 (1), P30AI054999 (1), R01HD053270 (1)